MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 377 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The company has six programs in clinical development and a pipeline of preclinical and research programs. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-Linked Retinitis Pigmentosa Associated with Mutations in the RPGR Gene; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the Treatment of LCA4. The company also provides AAV-hAQP1 for the Treatment of Radiation-Induced Grade 2/3 Xerostomia, AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy, AAV-RDH12 for the Treatment of RDH12 Mutation-Associated Retinal Dystrophy and others.